Swiss Atrial Fibrillation Cohort Study (SWISS-AF)

May 23, 2022 updated by: University Hospital, Basel, Switzerland

Swiss Atrial Fibrillation Cohort Study - SWISS AF

Swiss-AF is a prospective observational, multicentric cohort study in Switzerland. Overall, 2600 patients with documented atrial fibrillation aged >65 years will be included and followed on a yearly basis.

Yearly clinical examinations include a detailed questionnaire on personal characteristics, a resting electrocardiogram, neurocognitive function tests and questionnaires on disability and quality of life. Blood sampling and brain magnetic resonance imaging are scheduled at baseline and after 2 years of follow-up.

The main study aims of this long term prospective study are to increase our knowledge on structural brain damage and its changes over time in patients with atrial fibrillation, to gain additional insights on the incidence and underlying mechanisms of cognitive decline in patients with atrial fibrillation and to evaluate the interrelationships of structural and functional brain damage in this population.

Study Overview

Status

Active, not recruiting

Conditions

Study Type

Observational

Enrollment (Actual)

2415

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Switzerland
    • Basel-Stadt
      • Basel, Basel-Stadt, Switzerland, 4031
        • University Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

45 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

Consecutive patients with atrial fibrillation

Description

Inclusion Criteria:

  • atrial fibrillation documented within the last 24 months
  • age >=45 years

Exclusion Criteria:

  • acute illness
  • inability to provide informed consent
  • Only short episodes of reversible forms of atrial fibrillation

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Atrial Fibrillation
Cohort Study on patients with atrial fibrillation in Switzerland

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Stroke or systemic embolism
Time Frame: 2018 (after an average of 2.5 years of follow-up)
2018 (after an average of 2.5 years of follow-up)

Secondary Outcome Measures

Outcome Measure
Time Frame
Hospitalization for heart failure
Time Frame: 2018 (after an average of 2.5 years of follow-up)
2018 (after an average of 2.5 years of follow-up)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

University Hospital, Basel, Switzerland

Collaborators

Swiss National Science Foundation
Cardiocentro Ticino
Clinical Trial Unit, University Hospital Basel, Switzerland
Medical Image Analysis Center (MIAC) Basel
Schiller AG Baar
Cardiovascular Research Institute (CRIB) Basel

Investigators

  • Study Director: Stefan Osswald, MD, Prof., University Hospital, Basel, Switzerland
  • Principal Investigator: Michael Kuehne, MD, PD, exec. MBA, University Hospital, Basel, Switzerland
  • Principal Investigator: David Conen, MD MPH, McMaster University, Population Health Research Institute, Hamilton, Canada

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

March 1, 2014

Primary Completion (Anticipated)

March 1, 2030

Study Completion (Anticipated)

March 1, 2030

Study Registration Dates

First Submitted

March 28, 2014

First Submitted That Met QC Criteria

April 2, 2014

First Posted (Estimate)

April 7, 2014

Study Record Updates

Last Update Posted (Actual)

May 24, 2022

Last Update Submitted That Met QC Criteria

May 23, 2022

Last Verified

May 1, 2022

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • SWISS-AF

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Atrial Fibrillation

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Lithuania

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe